62
Participants
Start Date
July 17, 2001
Primary Completion Date
February 19, 2009
Study Completion Date
February 19, 2009
tipifarnib
Given orally, 200 mg/m\^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
placebo
Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
SUNY Upstate Medical University, NY (M1303), Syracuse
Childrens Hospital of Philadelphia, PA (M1257), Philadelphia
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
Johns Hopkins Oncology Center (M1011), Baltimore
University of Alabama at Birmingham (M1149), Birmingham
Cincinnati Children's Hospital (FWA 00002988), Cincinnati
Children's Memorial Hospital, Chicago, IL (M1484), Chicago
St. Louis Children's Hospital, St. Louis, MO (M1123), St Louis
Texas Children's Hospital, Houston, TX (M1060), Houston
Children's Hospital Los Angeles, CA (M1118), Los Angeles
The Children's Hospital, Dana-Farber Cancer Institute, Boston, MA (M1034), Boston
Klinikum Nord, Hamburg, Germany (FWA 00003228), Hamburg
National Cancer Institute (NCI)
NIH